MedPath

Autoreactivity Threshold Analysis in Lupus and Immune Thrombocytopenia (Checkpoints ITP and SLE)

Not Applicable
Conditions
Systemic Lupus Erythematosus (SLE)
Immune Thrombocytopenia (ITP)
Interventions
Other: Bliss-Believe
Registration Number
NCT03975361
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

The aim of this proposal is to test if anti-BAFF antibody can restore a normal threshold of tolerance in patients in two auto-immune diseases along the RITUX-PLUS study in immune thrombocytopenia, and along the Believe study in SLE. This work would help to conclude whether or not the 'double hit' therapy may help to reset the immune system toward a more tolerogenic profile.

The aim is to compare the polyreactivity and autoreactivity, of immature (central tolerance) and naïve B cells (peripheral tolerance) in the peripheral blood along the RITUX-PLUS STUDY and the BLISS BELIEVE study after treatment (B-cell reconstitution time).

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
10
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Bliss-BelieveBliss-BelievePatients included in the BLISS-BELIEVE study (NCT03312907).
Primary Outcome Measures
NameTimeMethod
Number of polyreactive and autoreactive cells in immature and naïve B cells subsets in the peripheral blood1 year

Number of polyreactive and autoreactive cells in immature (central tolerance) and naïve B cells (peripheral tolerance) subsets in the peripheral blood along the RITUX-PLUS and the BLISS BELIEVE studies after treatment (reconstitution time).

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (2)

Henri Mondor Hospital

🇫🇷

Créteil, France

Pitie Salpetriere Hospital

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath